Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Etsy Inc (ETSY) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

ETSY trades at $79.42, down 1.22% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.98, beating expectations, and raised its full-year outlook while announcing a 12% workforce reduction and a $2 billion share repurchase program. Revenue for 2025 was $2.88 billion with a net income margin of 5.65%, though equity remains negative at -$758.87 million due to retained earnings deficits.

The outlook is mixed: analyst consensus is a Buy with a $85.71 price target, reflecting optimism on operational efficiency and AI-driven growth, but risks include high debt, negative equity, and competitive pressures. The stock's valuation metrics like P/E of 25.15 and P/S of 3.54 suggest moderate pricing relative to peers, with cash flow stability from operations offering support amid restructuring.